glp-1/glucagon dual receptor agonist Schematic illustration of monoagonists, agonists and triple Glucagon-like Peptide-1 Receptor (GLP-1R) Signaling:
Description
13 Four of these have used ICP as an outcome measure, with the magnitude of treatment effect between trial arms ranging from 5.9 cmCSF (acetazolamide and diet), 41 6.0 (1.8) (by bariatric surgery) 12 and 6.2 cmCSF (through low-calorie diet)
A recent Federal Trade Commission (FTC) report highlighted that leading PBMs have significantly inflated pharmacy costs, impacting both employers and employees
Fibre supplementation has more consistent, though modest, evidence
Pediatric obesity and MASLD present significant long-term health risks, making early intervention crucial
